#ACTRIMS2021 – Young Brain Fluid (CSF) Rejuvenates Memory in Mice
Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021,…
Articles by Marisa Wexler, MS
#ACTRIMS2021 – Better Strategies Needed to Help Socioeconomically Disadvantaged Patients
Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021,…
Physical Inactivity, Smoking Linked to Patient Fatigue
People with multiple sclerosis (MS) who smoke tobacco or are not physically active are more likely to experience fatigue…
EVOLUTION Trials Testing Evobrutinib Now Recruiting
Two global Phase 3 clinical trials testing the investigational oral medication evobrutinib are recruiting participants with relapsing forms of…
Survey: Patients, Nurses Prefer Sensoready Autoinjector Pen
People with multiple sclerosis (MS) and their nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta…
Zeposia Tablets Approved in Scotland to Treat Active RRMS
The Scottish Medicines Consortium (SMC) has approved Zeposia (ozanimod) for the treatment of active relapsing-remitting multiple sclerosis (RRMS). Zeposia is…
Protein-targeting Therapy Found to Lessen Inflammation in Preclinical Study
A novel medication targeting the protein folate receptor-beta (FR-beta) decreased inflammation and brain damage in a rat model of…
FDA Approves Plegridy as Intramuscular Injection for Relapsing MS
The U.S. Food and Drug Administration (FDA) has approved an intramuscular injection formulation of Plegridy (peginterferon beta-1a) to treat people…
CHMP Favors Kesimpta for Adults With Relapsing MS in Europe
A branch of the European Medicines Agency (EMA) has recommended that Kesimpta (ofatumumab) be approved and made available to treat…
NfL Mirrors Some Life Quality Aspects Felt by Patients, More Work Needed
Levels of neurofilament light (NfL), a protein marker of neuronal damage, appear to capture some aspects of patient‐perceived physical and…
Levels of Fatty Acid Low in MS Patients, Likely Affecting Immune System
Oleic acid, a type of fatty acid, is important for the function of immune cells that are dysregulated in…
Clene Awaits US Patent Covering Gold Nanocrystals’ Use in Treating MS
Clene Nanomedicine has been notified it will be given a U.S. patent, as requested, covering an invention using the…
Helius Provides More Information to FDA About PoNS Device
Helius Medical Technologies has submitted its response to the U.S. Food and Drug Administration (FDA)’s request…
Target Tissues of Immune Attacks Too Often Ignored in Research, Study Says
To fully understand autoimmune diseases like multiple sclerosis (MS), it is necessary to study not just the immune system,…
MSAA Hosting 8th Webinar on COVID-19 and MS
The Multiple Sclerosis Association of America (MSAA) is hosting a webinar in which experts will discuss the COVID-19 pandemic…
Study Seeks to Better Understand How MS Affects Memory
A new research project will seek to better understand the biological processes that drive memory problems in people with…
Tablet-based Video Game Could Help Measure Cognitive Impairment in MS, Study Shows
People with multiple sclerosis (MS) may have cognitive defects that cannot be detected using conventional paper-and-pen tests but that can…
ChariotMS to Test Mavenclad in SPMS, PPMS Patients With Little Ability to Walk
An upcoming Phase 2 clinical trial, called ChariotMS, will test whether Mavenclad (cladribine) can slow a worsening of…
Software Platform May Allow for Automated MS Cognitive Testing
A software platform, called CogniSoft, allows for automated assessments of cognitive health in people with multiple sclerosis (MS). The…
New MS Trust Funding Will Help Improve Patient Support During Pandemic
The U.K.’s MS Trust has been awarded £50,000 (about $65,800) from the Coronavirus Community Support Fund — distributed by…
Neurofilament Light Levels at First MS Event Can Predict Long-term Brain Atrophy
The levels of the protein neurofilament light chain (NfL) in the blood when a person experiences a first demyelinating…
Mavenclad for RRMS Now Available Through Seven Provincial Public Drugs Plans in Canada
Eligible people with relapsing-remitting multiple sclerosis (RRMS) now have access to Mavenclad (cladribine) through seven provincial public drug plans in…
Recently Identified Subset of Immune Cells Plays Role in MS, Study Suggests
A newly identified population of immune cells contributes to inflammation in multiple sclerosis (MS), a new study suggests. The…
Variation in Given Gene May Raise Depression Risk Among MS Patients
A genetic variant may make depression more likely in certain people with multiple sclerosis (MS) than others, a genome-wide study in…
Mayzent Approved for Active SPMS Patients in England and Wales
Mayzent (siponimod) has become the first oral medication to be approved for people with active secondary progressive multiple…
Health Canada Approves Oral Zeposia for Adults With RRMS
Health Canada has approved Zeposia (ozanimod), an oral daily treatment for people with relapsing-remitting multiple sclerosis (RRMS) in…
Differences Found in Brain Connectivity in RRMS Patients During Visual Task
Connectivity between parts of the brain related to vision and attention is altered in people with relapsing-remitting multiple sclerosis…
Gilenya and Tecfidera Similarly Effective at Treating RRMS, Real-world Study Says
Gilenya (fingolimod) and Tecfidera (dimethyl fumarate) are similarly effective at lowering the frequency of relapses and delaying disability…
Anokion Planning Launch of Phase 1 Trial of Investigational MS Therapy ANK-700
The U.S. Food and Drug Administration (FDA) has accepted an investigational new drug application (IND) for ANK-700,…
Medical Cannabis Lozenges Now Available for MS Patients in Texas
People in Texas with multiple sclerosis (MS) and other medical conditions now have access to cannabis-infused lozenges,…